Esperion Therapeutics (ESPR) Retained Earnings (2012 - 2026)

Esperion Therapeutics' Retained Earnings history runs 15 years deep, the most recent figure standing at -$1.6 billion for Q1 2026.

• Quarterly Retained Earnings fell 229.83% year-over-year to -$1.6 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$1.6 billion (down 229.83% YoY) and the FY2025 annual result came in at -$1.6 billion, down 1.42% from the prior year.
• Retained Earnings was -$1.6 billion for Q1 2026 at Esperion Therapeutics, down from -$1.6 billion in the prior quarter.
• Across five years, Retained Earnings topped out at $1.3 billion in Q3 2025 and bottomed at -$1.6 billion in Q1 2026.
• A 5-year average of -$336.9 million and a median of -$1.3 billion in 2022 frame the typical range for Retained Earnings.
• Annual changes were most pronounced in 2022 — Retained Earnings soared 202.17% — and 2024, when it tumbled 232.05%.
• Esperion Therapeutics' Retained Earnings stood at -$1.3 billion in 2022, then retreated by 15.62% to -$1.5 billion in 2023, then slipped by 3.34% to -$1.6 billion in 2024, then fell by 1.42% to -$1.6 billion in 2025, then decreased by 1.55% to -$1.6 billion in 2026.
• Business Quant data shows ESPR's Retained Earnings at -$1.6 billion in Q1 2026, -$1.6 billion in Q4 2025, and $1.3 billion in Q3 2025.